Breast Cancer 1, Early Onset (BRCA1) antibody

Antigen: Breast Cancer 1, Early Onset (BRCA1)

Synonyms: BRCA1, iris, pscp, brcai, brcc1, rnf53, brca1, LOC100224649, IRIS, PSCP, BRCAI, BRCC1, RNF53, BROVCA1, ARABIDOPSIS THALIANA BREAST CANCER SUSCEPTIBILITY1, ATBRCA1, breast cancer susceptibility1

Clonality: Monoclonal (GLK-2)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (IHC)

Catalog no.: ABIN115263

Additional Information

Alternative name: BRCA1 / RNF53

UniProt: P38398

Immunogen: Peptide corresponding to amino acids 1839-1863 of the c-terminus of BRCA1

Cross-Reactivity: Human

Isotype: IgM

Clone: GLK-2

Description: BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein thatplays a role in maintaining genomic stability and acts as a tumor suppressor. It combineswith other tumor suppressors, DNA damage sensors, and signal transducers to form a largemulti-subunit protein complex known as BASC (for BRCA1 associated genome surveillancecomplex). BRCA1 associates with RNA polymerase II, and through the C terminal domain,also interacts with histone deacetylase complex. This protein thus plays a role intranscription, DNA repair of double-stranded breaks, and recombination. Mutations in theBRCA1 gene are responsible for approximately 40% of inherited breast cancers and morethan 80% of inherited breast and ovarian cancers. Alternative splicing plays a role inmodulating the subcellular localization and physiological function of this gene. Manyalternatively spliced transcript variants have been described for this gene but only somehave had their full length natures identified.

Characteristics: Synonyms: Breast cancer type 1 susceptibility protein, RING finger protein 53

Specificity: BRCA1 recognizes a 22 kD protein. This antibody stains 94 % of ovarian carcinomas with amutation in exon 11. However, staining was absent in 100 % of tumors with mutations otherthan exon 11. Cellular Localization: Cytoplasmic. Species: Human. Others not tested.

Application Details

Application Notes: Immunohistochemistry on frozen and paraffin sections (ABC method: 1/15 - 1/50, Formalinfixed paraffin embedded tissue sections require high temperature antigen unmasking with10 mM citrate buffer, pH 6.0 prior to immunostaining, Incubation period of 30-60 minutesat room temperature). Use ovarian carcinoma as positive control. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Concentration: n.d.

Purification: Supernatant

Buffer: Tissue culture supernatant with 0.05 % sodium azide as preservative

Storage: Store the antibody undiluted at 2-8°C for one month or at -20°C for longer. Avoid repeatedfreezing and thawing. Should this product contain a precipitate we recommendmicrocentrifugation before use. Shelf life: One year from despatch.

Restrictions: For Research Use only

Publications

Bur, Zimarowski, Schnitt et al.: "Estrogen receptor immunohistochemistry in carcinoma in situ of the breast." in: Cancer, Vol. 69, Issue 5, pp. 1174-81, 1992 (PubMed).

Graham, Jin, Lloyd: "Detection of estrogen receptor in paraffin-embedded sections of breast carcinoma by immunohistochemistry and in situ hybridization." in: The American journal of surgical pathology, Vol. 15, Issue 5, pp. 475-85, 1991 (PubMed).

Pertschuk, Kim, Nayer et al.: "Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival." in: Cancer, Vol. 66, Issue 8, pp. 1663-70, 1990 (PubMed).

Kumar, Green, Stack et al.: "Functional domains of the human estrogen receptor." in: Cell, Vol. 51, Issue 6, pp. 941-51, 1988 (PubMed).